Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221-223).
|Number of pages||2|
|Publication status||Published - Feb 2012|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)